GSK To Co-Promote Advair With Mitsubishi Tanabe Pharma In Japan
This article was originally published in PharmAsia News
GlaxoSmithKline and Mitsubishi Tanabe Pharma will be co-promoting chronic obstructive pulmonary disease treating Advair Diskus (fluticasone propionate plus salmeterol) staring April. Through the collaboration, GSK aims to increase awareness and provide Japanese patients information on the drug as a treatment option. In Japan, there are 4.5 million COPD patients and 2,500 people die of the disease annually. (Click here for more - Japanese language)
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.